Seven stocks that could safely increase tenfold by 2030

In the market, especially in the short-term, there is no such thing as safe profit. However, in the long term, many assets are very solid and do not disappoint investors. Major exchanges like Gate often pay a premium for these solid companies, but purchasing companies that have huge growth potential and rapidly expanding margins may bring good fortune.

While these selections may not guarantee a tenfold increase in stock prices by 2030, I am confident that if they continue to deliver strong performance as they have, they will at least provide returns that exceed the market average. Purchasing companies that are solidly profitable and possess significant competitive advantages is a time-tested method for achieving substantial profits.

Here are seven stocks that have the potential to increase tenfold.

Cloudflare (NET)

Cloudflare provides essential internet security and performance services for a large part of the web. With a 97.81% share of the cloud security market, Cloudflare, which has a customer base primarily composed of small to medium-sized websites, has become an indispensable player in a world that is increasingly digital. I believe that its dominance in this market and the continual growth of internet usage create a wide and sustainable moat around Cloudflare's business.

In the first quarter of 2024, the company showed solid growth. It achieved revenues of $378.6 million, a 30% increase compared to the same period last year, expanded its margins, and generated $35.6 million in free cash flow. The growth of large customers was particularly impressive, with record numbers of contracts worth over $100,000, over $500,000, and over $1 million.

What is most exciting is that Cloudflare is only scratching the surface of its long term profit potential. EPS is expected to surge from 61 cents in 2024 to $9.80 by 2033, and revenues are expanding toward $15 billion.

I believe that Cloudflare is one of the rare companies with true 10x growth potential over the next decade.

Insulet (PODD)

Insulet manufactures tubeless insulin pump technology for diabetes patients. The company's first quarter performance greatly exceeded expectations, with revenue reaching $441.7 million, a 23% increase compared to the same period last year. Insulet's automated insulin delivery system, Omnipod 5, is driving this momentum as an evident market leader.

I believe that Insulet will unfortunately benefit greatly from the global obesity epidemic. As waistlines expand, the target market for Insulet's innovative diabetes management solutions will also grow. Approximately 25% of Insulet's new Omnipod customers are type 2 diabetes patients, which indicates significant potential for future growth.

Insulet's valuation is indeed high, but I would like to avoid betting on this disruptive innovator. The management has revised its full-year guidance upwards. This stock is never cheap, but if Insulet can maintain significant EPS outperformance for two consecutive years, it could be one of the stocks that has the potential to increase tenfold by 2030. GuruFocus's DCF model also predicts a promising trend.

Paycom (PAYC)

Paycom offers cloud-based human resource management software solutions. The stock price has fallen 73% from its peak in 2021, but I believe this sell-off is excessive and that Paycom is poised for a significant rebound.

In the first quarter of 2024, Paycom delivered impressive results, with EPS coming in at $2.59, exceeding expectations by 12 cents. Additionally, revenue rose to nearly $500 million, up 10.7% year-over-year, also surpassing forecasts. The company has a remarkable track record of exceeding expectations in both revenue and profit every year for the past decade. Looking at the financial situation, there is no indication of a scenario where the stock price would plummet.

The most exciting aspect is the huge market opportunity. About 40% of companies still rely on outdated offline HCM solutions. As these companies rush to modernize and automate their HR processes, Paycom is in the perfect position to capitalize on this trend. Beti has already brought significant ROI to customers and is driving Paycom's growth.

A 10-fold return may be ambitious, but Paycom has the potential to bring several times the profit in the coming years.

Flywire (FLYW)

Flywire provides payment solutions for the education, healthcare, travel, and B2B industries. Although revenue exceeded expectations, the Q1 EPS fell short of forecasts by 9 cents, causing the stock price to drop over 68% from its peak. I believe this short-term weakness presents a long term investment opportunity.

Flywire's revenue showed impressive growth, increasing by 24% year-over-year to $100.1 million, and it currently has over 4,000 clients in more than 50 countries. It can process payments in over 140 currencies from more than 240 countries and regions. This incredible global reach indicates that Flywire is well-positioned to capitalize on the massive growth potential in the end market.

The recent slowdown in international student visa approvals is certainly a headwind. However, the core financial situation is very strong. Adjusted EBITDA continues to expand with solid growth, and the top line is similarly performing well. I believe that Flywire's current valuation represents a great entry point for patient investors. The overall weakness in the fintech industry will not last forever, and Flywire seems to be one of the stocks that could potentially multiply tenfold by 2030. Analysts see a 64% upside potential just over the next 12 months.

Genmab (GMAB)

Genmab is a biotechnology company that develops antibody therapeutics for cancer treatment. I expect the company's EPS to increase by about five times over the next four years, indicating strong upside potential. In the first quarter, Genmab reported impressive results, with revenue increasing by 46% to DKK 4.143 billion. The margins here appear to be notably good.

The company's future is bright, bolstered by the continued success of epcoritamab. Epcoritamab has received approvals in various regions for relapsed or refractory diffuse large B-cell lymphoma. Genmab and its partner AbbVie have a robust development plan and have initiated the first of multiple phase 3 trials for follicular lymphoma. Furthermore, the FDA has granted priority review for EPKINLY for relapsed or refractory follicular lymphoma.

Another milestone was the full FDA approval of Tivdak for recurrent or metastatic cervical cancer. This made Tivdak the first ADC to demonstrate survival benefits. Of course, investing in biotechnology requires a stroke of luck, but I am optimistic here. This is undoubtedly one of the stocks that could potentially multiply tenfold if everything goes well.

Sprout Social (SPT)

Sprout Social provides a social media management platform for businesses. I believe that this company is in a good position to benefit from the increasing influence of social media over the next few years. People are spending hours each week on various social platforms. The tools from Sprout Social may be in very high demand due to these trends.

In the first quarter of 2024, Sprout Social reported solid performance, with revenue reaching $96.8 million, a 28.7% increase compared to the same period last year, although it slightly missed expectations. Additionally, EPS recorded an impressive upside surprise at $0.10 against the expected $0.01. Looking ahead, analysts forecast a robust annual revenue growth of about 20% until 2028.

If Sprout Social can execute its growth plan, EPS could expand from 47 cents in 2024 to over 2 dollars by 2028. There are risks involved, but I believe that if they can capitalize on the enormous social media opportunities, it has the potential to yield several times the returns by 2030.

This relatively unknown company is one of the stocks to watch in the coming years.

Baidu (BIDU)

Baidu is a leading technology company in China focused on AI and cloud computing. While a 10x return by 2030 may be difficult, I believe there is significant upside potential in the long term.

The company's performance in the first quarter showed promising signs, with Baidu Core's revenue reaching 31.5 billion yuan, a 1% increase compared to the same period last year. Baidu's ERNIE AI model is being rapidly adopted, with API calls skyrocketing from 50 million in December to 200 million in April. This indicates the strength of future revenue potential in model inference.

The mobile business may experience a soft trend in the near future, but as generative AI becomes the new core of Baidu's products, a recovery is expected next year. The company is building a strong ecosystem centered around ERNIE, which could include millions of applications.

As China further advances its monetary easing and EPS recovers, stock prices are expected to rebound.